The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adult Malignant Glioma Therapeutics Market Research Report 2025
Synopsis
Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.
The global Adult Malignant Glioma Therapeutics market was valued at US$ 1292.1 million in 2023 and is anticipated to reach US$ 1901.4 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adult Malignant Glioma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adult Malignant Glioma Therapeutics.
Report Scope
The Adult Malignant Glioma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adult Malignant Glioma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adult Malignant Glioma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Novocure
Eli Lilly
AstraZeneca
Novartis AG
Bayer
Emcure Pharmaceuticals
Segment by Type
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other
Segment by Application
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adult Malignant Glioma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.
The global Adult Malignant Glioma Therapeutics market was valued at US$ 1292.1 million in 2023 and is anticipated to reach US$ 1901.4 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adult Malignant Glioma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adult Malignant Glioma Therapeutics.
Report Scope
The Adult Malignant Glioma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adult Malignant Glioma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adult Malignant Glioma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Novocure
Eli Lilly
AstraZeneca
Novartis AG
Bayer
Emcure Pharmaceuticals
Segment by Type
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other
Segment by Application
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adult Malignant Glioma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Glioblastoma Multiforme
1.2.3 Anaplastic Astrocytoma
1.2.4 Anaplastic Oligodendroglioma
1.2.5 Other
1.3 Market by Application
1.3.1 Global Adult Malignant Glioma Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Cancer and Radiation Therapy Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adult Malignant Glioma Therapeutics Market Perspective (2019-2030)
2.2 Adult Malignant Glioma Therapeutics Growth Trends by Region
2.2.1 Global Adult Malignant Glioma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Adult Malignant Glioma Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Adult Malignant Glioma Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Adult Malignant Glioma Therapeutics Market Dynamics
2.3.1 Adult Malignant Glioma Therapeutics Industry Trends
2.3.2 Adult Malignant Glioma Therapeutics Market Drivers
2.3.3 Adult Malignant Glioma Therapeutics Market Challenges
2.3.4 Adult Malignant Glioma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adult Malignant Glioma Therapeutics Players by Revenue
3.1.1 Global Top Adult Malignant Glioma Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Adult Malignant Glioma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Adult Malignant Glioma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adult Malignant Glioma Therapeutics Revenue
3.4 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio
3.4.1 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adult Malignant Glioma Therapeutics Revenue in 2023
3.5 Adult Malignant Glioma Therapeutics Key Players Head office and Area Served
3.6 Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
3.7 Date of Enter into Adult Malignant Glioma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adult Malignant Glioma Therapeutics Breakdown Data by Type
4.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2025-2030)
5 Adult Malignant Glioma Therapeutics Breakdown Data by Application
5.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Adult Malignant Glioma Therapeutics Market Size (2019-2030)
6.2 North America Adult Malignant Glioma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024)
6.4 North America Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adult Malignant Glioma Therapeutics Market Size (2019-2030)
7.2 Europe Adult Malignant Glioma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024)
7.4 Europe Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Adult Malignant Glioma Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adult Malignant Glioma Therapeutics Market Size (2019-2030)
9.2 Latin America Adult Malignant Glioma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Adult Malignant Glioma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Adult Malignant Glioma Therapeutics Introduction
11.1.4 Merck Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Hoffmann-La Roche
11.2.1 Hoffmann-La Roche Company Detail
11.2.2 Hoffmann-La Roche Business Overview
11.2.3 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Introduction
11.2.4 Hoffmann-La Roche Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.2.5 Hoffmann-La Roche Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Detail
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Adult Malignant Glioma Therapeutics Introduction
11.4.4 Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Detail
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Adult Malignant Glioma Therapeutics Introduction
11.5.4 AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.5.5 AbbVie Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Adult Malignant Glioma Therapeutics Introduction
11.6.4 Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Detail
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Sun Pharmaceutical
11.8.1 Sun Pharmaceutical Company Detail
11.8.2 Sun Pharmaceutical Business Overview
11.8.3 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Introduction
11.8.4 Sun Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.8.5 Sun Pharmaceutical Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Introduction
11.9.4 Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Novocure
11.10.1 Novocure Company Detail
11.10.2 Novocure Business Overview
11.10.3 Novocure Adult Malignant Glioma Therapeutics Introduction
11.10.4 Novocure Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.10.5 Novocure Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Adult Malignant Glioma Therapeutics Introduction
11.11.4 Eli Lilly Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.11.5 Eli Lilly Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Adult Malignant Glioma Therapeutics Introduction
11.12.4 AstraZeneca Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.12.5 AstraZeneca Recent Development
11.13 Novartis AG
11.13.1 Novartis AG Company Detail
11.13.2 Novartis AG Business Overview
11.13.3 Novartis AG Adult Malignant Glioma Therapeutics Introduction
11.13.4 Novartis AG Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.13.5 Novartis AG Recent Development
11.14 Bayer
11.14.1 Bayer Company Detail
11.14.2 Bayer Business Overview
11.14.3 Bayer Adult Malignant Glioma Therapeutics Introduction
11.14.4 Bayer Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.14.5 Bayer Recent Development
11.15 Emcure Pharmaceuticals
11.15.1 Emcure Pharmaceuticals Company Detail
11.15.2 Emcure Pharmaceuticals Business Overview
11.15.3 Emcure Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
11.15.4 Emcure Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024)
11.15.5 Emcure Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Glioblastoma Multiforme
Table 3. Key Players of Anaplastic Astrocytoma
Table 4. Key Players of Anaplastic Oligodendroglioma
Table 5. Key Players of Other
Table 6. Global Adult Malignant Glioma Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Adult Malignant Glioma Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Adult Malignant Glioma Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Adult Malignant Glioma Therapeutics Market Share by Region (2019-2024)
Table 10. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Adult Malignant Glioma Therapeutics Market Share by Region (2025-2030)
Table 12. Adult Malignant Glioma Therapeutics Market Trends
Table 13. Adult Malignant Glioma Therapeutics Market Drivers
Table 14. Adult Malignant Glioma Therapeutics Market Challenges
Table 15. Adult Malignant Glioma Therapeutics Market Restraints
Table 16. Global Adult Malignant Glioma Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Adult Malignant Glioma Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2023)
Table 19. Ranking of Global Top Adult Malignant Glioma Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Adult Malignant Glioma Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
Table 23. Date of Enter into Adult Malignant Glioma Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Adult Malignant Glioma Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Adult Malignant Glioma Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Adult Malignant Glioma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Adult Malignant Glioma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Adult Malignant Glioma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Merck Company Detail
Table 49. Merck Business Overview
Table 50. Merck Adult Malignant Glioma Therapeutics Product
Table 51. Merck Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Merck Recent Development
Table 53. Hoffmann-La Roche Company Detail
Table 54. Hoffmann-La Roche Business Overview
Table 55. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Product
Table 56. Hoffmann-La Roche Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Hoffmann-La Roche Recent Development
Table 58. Arbor Pharmaceuticals Company Detail
Table 59. Arbor Pharmaceuticals Business Overview
Table 60. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Product
Table 61. Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Arbor Pharmaceuticals Recent Development
Table 63. Pfizer Company Detail
Table 64. Pfizer Business Overview
Table 65. Pfizer Adult Malignant Glioma Therapeutics Product
Table 66. Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. AbbVie Company Detail
Table 69. AbbVie Business Overview
Table 70. AbbVie Adult Malignant Glioma Therapeutics Product
Table 71. AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 72. AbbVie Recent Development
Table 73. Amgen Company Detail
Table 74. Amgen Business Overview
Table 75. Amgen Adult Malignant Glioma Therapeutics Product
Table 76. Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 77. Amgen Recent Development
Table 78. Bristol-Myers Squibb Company Detail
Table 79. Bristol-Myers Squibb Business Overview
Table 80. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Product
Table 81. Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Bristol-Myers Squibb Recent Development
Table 83. Sun Pharmaceutical Company Detail
Table 84. Sun Pharmaceutical Business Overview
Table 85. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Product
Table 86. Sun Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Sun Pharmaceutical Recent Development
Table 88. Teva Pharmaceutical Company Detail
Table 89. Teva Pharmaceutical Business Overview
Table 90. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Product
Table 91. Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Teva Pharmaceutical Recent Development
Table 93. Novocure Company Detail
Table 94. Novocure Business Overview
Table 95. Novocure Adult Malignant Glioma Therapeutics Product
Table 96. Novocure Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Novocure Recent Development
Table 98. Eli Lilly Company Detail
Table 99. Eli Lilly Business Overview
Table 100. Eli Lilly Adult Malignant Glioma Therapeutics Product
Table 101. Eli Lilly Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 102. Eli Lilly Recent Development
Table 103. AstraZeneca Company Detail
Table 104. AstraZeneca Business Overview
Table 105. AstraZeneca Adult Malignant Glioma Therapeutics Product
Table 106. AstraZeneca Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 107. AstraZeneca Recent Development
Table 108. Novartis AG Company Detail
Table 109. Novartis AG Business Overview
Table 110. Novartis AG Adult Malignant Glioma Therapeutics Product
Table 111. Novartis AG Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 112. Novartis AG Recent Development
Table 113. Bayer Company Detail
Table 114. Bayer Business Overview
Table 115. Bayer Adult Malignant Glioma Therapeutics Product
Table 116. Bayer Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 117. Bayer Recent Development
Table 118. Emcure Pharmaceuticals Company Detail
Table 119. Emcure Pharmaceuticals Business Overview
Table 120. Emcure Pharmaceuticals Adult Malignant Glioma Therapeutics Product
Table 121. Emcure Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2019-2024) & (US$ Million)
Table 122. Emcure Pharmaceuticals Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adult Malignant Glioma Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Adult Malignant Glioma Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Glioblastoma Multiforme Features
Figure 4. Anaplastic Astrocytoma Features
Figure 5. Anaplastic Oligodendroglioma Features
Figure 6. Other Features
Figure 7. Global Adult Malignant Glioma Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Adult Malignant Glioma Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Cancer and Radiation Therapy Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Adult Malignant Glioma Therapeutics Report Years Considered
Figure 14. Global Adult Malignant Glioma Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Adult Malignant Glioma Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Adult Malignant Glioma Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Adult Malignant Glioma Therapeutics Market Share by Players in 2023
Figure 18. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Adult Malignant Glioma Therapeutics Revenue in 2023
Figure 20. North America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Adult Malignant Glioma Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Adult Malignant Glioma Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Adult Malignant Glioma Therapeutics Market Share by Region (2019-2030)
Figure 34. China Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Adult Malignant Glioma Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Adult Malignant Glioma Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Merck Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 49. Hoffmann-La Roche Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 50. Arbor Pharmaceuticals Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 51. Pfizer Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 52. AbbVie Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 53. Amgen Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 55. Sun Pharmaceutical Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 56. Teva Pharmaceutical Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 57. Novocure Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 58. Eli Lilly Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 59. AstraZeneca Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 60. Novartis AG Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 61. Bayer Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 62. Emcure Pharmaceuticals Revenue Growth Rate in Adult Malignant Glioma Therapeutics Business (2019-2024)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
